Format

Send to

Choose Destination
Am J Med Genet A. 2017 Jun;173(6):1562-1565. doi: 10.1002/ajmg.a.38221. Epub 2017 Apr 21.

Aneurysms in neurofibromatosis type 2: Evidence for vasculopathy?

Author information

1
Department of Neurology, Guy's and St. Thomas' NHS Trust, London, UK.
2
Department of Radiology, King's College and Neurofibromatosis Unit, London, UK.
3
Department of Neurosurgery, King's College, London, UK.

Abstract

There have been anecdotal reports of vasculopathy associated with Neurofibromatosis Type 2 (NF2). Given the increasing use of bevacizumab, a vascular endothelial growth factor inhibitor which results in an increased risk of bleeding, it is important to ascertain if there is a predisposition to vascular abnormalities in NF2. In our unit NF2 patients undergo annual MRI brain and internal auditory meatus imaging. We noted incidental intracranial aneurysms in some patients and sought to determine the prevalence of intracranial aneurysms in our cohort of NF2 patients. We conducted a retrospective audit of the MRI images of 104 NF2 patients from 2014 to 2016. Axial T2 brain MRI images were assessed for vascular abnormalities by two neuroradiologists blinded to patient's clinical details. Intracranial aneurysms were detected in four patients and an aneurysm clip related to previous surgery was noted in one additional patient. Using standard MRI imaging sequences alone we provide evidence of intracranial aneurysms in 4.4% of our cohort. This compares with an estimated overall prevalence of 3% in the general population. We discuss these findings as well as other evidence for a vasculopathy associated with NF2.

KEYWORDS:

aneurysm; neurofibromatosis 2; vasculopathy

PMID:
28429859
DOI:
10.1002/ajmg.a.38221
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center